Piper Sandler Downgrades Ardelyx(ARDX.US) to Hold Rating, Cuts Target Price to $7
Piper Sandler Sticks to Their Hold Rating for Ardelyx (ARDX)
HC Wainwright & Co. Reiterates Buy on Ardelyx, Maintains $10 Price Target
Ardelyx Analyst Ratings
Wedbush Sticks to Its Buy Rating for Ardelyx (ARDX)
Ardelyx's Strategic Response to Regulatory Challenges: A High-Risk Buy Rating With Potential for Substantial Return
Ardelyx Analyst Ratings
Wedbush Adjusts Ardelyx's Price Target to $11 From $15, Keeps Outperform Rating
Ardelyx Analyst Ratings
Ardelyx Analyst Ratings
Wedbush Reiterates Outperform on Ardelyx, Maintains $15 Price Target
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ardelyx (ARDX), Cogent Biosciences (COGT) and Immunocore Holdings (IMCR)
Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)
Citi: Maintains the Ardelyx (ARDX.US) rating, adjusted from buy to buy rating, and adjusted the target price from $13.00 to $14.00.
Ardelyx Analyst Ratings
Citigroup Maintains Buy on Ardelyx, Raises Price Target to $14
Ardelyx Analyst Ratings
Wedbush Maintains Outperform on Ardelyx, Raises Price Target to $15
Wedbush Remains a Buy on Ardelyx (ARDX)
Piper Sandler Sticks to Their Buy Rating for Ardelyx (ARDX)
No Data